胆汁酸在肝肠疾病中的免疫调节作用

doi:10.6040/j.issn.1671-7554.0.2021.0924

摘要/Abstract

摘要： 胆汁酸是胆固醇在肝脏中分解代谢的最终产物,是胆汁的主要成分,主要用于乳化脂类物质,促进脂类物质吸收。胆汁酸代谢失调与多种肝肠疾病,包括肝细胞肝癌、结直肠癌的发生发展密切相关;针对胆汁酸的药物在临床广泛应用。免疫细胞在肝肠疾病的进程中发挥重要作用,胆汁酸与肝肠免疫关系密切,影响多种免疫细胞的分化与功能,进而影响疾病的发生发展进程。综述了胆汁酸对肝肠免疫细胞的调控作用,以期为利用胆汁酸开发新型肝肠疾病治疗手段提供帮助。

关键词: 胆汁酸, 胆汁酸受体, 肝肠炎症, 免疫稳态, 免疫细胞

Abstract: Bile acid, the final product of cholesterol catabolism in liver and the main component of bile, is critical for the emulsification and absorption of lipids. Dysregulation of bile acid metabolism is closely related to various hepatic and intestinal diseases, including hepatocellular carcinoma and colorectal cancer. At present, the clinical drugs targeting bile acid are widely utilized. Immune cells play an important role in the process of hepatointestinal diseases. Bile acid is closely related to liver and intestine immune homeostasis, affecting the differentiation and function of various immune cells, and thus affecting the occurrence and development of diseases. In this paper, we will review the regulation effect of bile acid on hepatointestinal immune cells in order to develop new therapeutic methods for hepatointestinal diseases by using bile acid.

Key words: Bile acid, Bile acid receptor, Hepatointestinal inflammation, Immune homeostasis, Immune cells

中图分类号:

R575.203

张召英,马春红. 胆汁酸在肝肠疾病中的免疫调节作用[J]. 山东大学学报 (医学版), 2021, 59(9): 30-36.

ZHANG Zhaoying, MA Chunhong. Immunomodulatory effects of bile acid in hepatointestinal diseases[J]. Journal of Shandong University (Health Sciences), 2021, 59(9): 30-36.

参考文献

[1] Winston JA, Theriot CM. Diversification of host bile acids by members of the gut microbiota [J]. Gut Microbes, 2020, 11(2): 158-171.
[2] Frank GS, Michael T, Peter LMJ. Bile acid receptors as targets for drug development [J]. Nat Rev Gastroenterol Hepatol, 2014, 11(1): 55-67.
[3] Schubert K, Olde Damink SWM, von Bergen M, et al. Interactions between bile salts, gut microbiota, and hepatic innate immunity [J]. Immunol Rev, 2017, 279(1): 23-35.
[4] Jiang Y, Iakova P, Jin J, et al. Farnesoid X receptor inhibits gankyrin in mouse livers and prevents development of liver cancer [J]. Hepatology, 2013, 57(3): 1098-1106.
[5] Kim I, Morimura K, Shah Y, et al. Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice [J]. Carcinogenesis, 2007, 28(5): 940-946.
[6] Fu T, Coulter S, Yoshihara E, et al. FXR regulates intestinal cancer stem cell proliferation [J]. Cell, 2019, 176(5): 1098-1112.
[7] Younossi ZM, Ratziu V, Loomba R, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial [J]. Lancet, 2019, 394(10215): 2184-2196.
[8] Reich M, Klindt C, Deutschmann K, et al. Role of the G protein-coupled bile acid receptor TGR5 in liver damage [J]. Dig Dis, 2017, 35(3): 235-240.
[9] Yang F, Mao C, Guo L, et al. Structural basis of GPBAR activation and bile acid recognition [J]. Nature, 2020, 587(7834): 499-504.
[10] Xie G, Wang X, Liu P, et al. Distinctly altered gut microbiota in the progression of liver disease [J]. Oncotarget, 2016, 7(15): 19355-19366.
[11] Xie G, Wang X, Huang F, et al. Dysregulated hepatic bile acids collaboratively promote liver carcinogenesis [J]. Int J Cancer, 2016, 139(8): 1764-1775.
[12] Bajaj JS, Kakiyama G, Zhao D, et al. Continued alcohol misuse in human cirrhosis is associated with an impaired gut-liver axis [J]. Alcohol Clin Exp Res, 2017, 41(11): 1857-1865.
[13] König A, Döring B, Mohr C, et al. Kinetics of the bile acid transporter and hepatitis B virus receptor Na+/taurocholate cotransporting polypeptide(NTCP)in hepatocytes [J]. J Hepatol, 2014, 61(4): 867-875.
[14] Kim HY, Cho HK, Choi YH, et al. Bile acids increase hepatitis B virus gene expression and inhibit interferon-alpha activity [J]. Febs J, 2010, 277(13): 2791-2802.
[15] Li Y, Tang R, Leung PSC, et al. Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases [J]. Autoimmun Rev, 2017, 16(9): 885-896.
[16] Duboc Henri, Rajca S, Rainteau D, et al. Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases [J]. Gut, 2013, 62(4): 531-539.
[17] Ajouz H, Mukherji D, Shamseddine A. Secondary bile acids: an underrecognized cause of colon cancer [J]. World J Surg Oncol, 2014, 12: 164. doi:10.1186/1477-7819-12-164.
[18] Ridlon JM, Bajaj JS. The human gut sterolbiome: bile acid-microbiome endocrine aspects and therapeutics [J]. Acta Pharm Sin B, 2015, 5(2): 99-105.
[19] Chaudhari SN, Luo JN, Harris DA, et al. A microbial metabolite remodels the gut-liver axis following bariatric surgery [J]. Cell Host Microbe, 2021, 29(3): 408-424.
[20] Li M, Cai SY, Boyer JL. Mechanisms of bile acid mediated inflammation in the liver [J]. Mol Aspects Med, 2017, 56: 45-53. doi:10.1016/j.mam.2017.06.001.
[21] Cai SY, Ouyang X, Chen Y, et al. Bile acids initiate cholestatic liver injury by triggering a hepatocyte-specific inflammatory response [J]. JCI Insight, 2017, 2(5): e90780.
[22] Jiang X, Lian M, Li Y, et al. The immunobiology of mucosal-associated invariant T cell(MAIT)function in primary biliary cholangitis: Regulation by cholic acid-induced Interleukin-7 [J]. J Autoimmun, 2018, 90: 64-75. doi:10.1016/j.jaut.2018.01.007.
[23] Gong Z, Zhou J, Zhao S, et al. Chenodeoxycholic acid activates NLRP3 inflammasome and contributes to cholestatic liver fibrosis [J]. Oncotarget, 2016, 7(51): 83951-83963.
[24] Hao H, Cao L, Jiang C, et al. Farnesoid X receptor regulation of the NLRP3 inflammasome underlies cholestasis-associated Sepsis [J]. Cell Metab, 2017, 25(4): 856-867.
[25] Biagioli M, Carino A, Cipriani S, et al. The bile acid receptor GPBAR1 regulates the M1/M2 phenotype of intestinal macrophages and activation of GPBAR1 rescues mice from murine colitis [J]. J Immunol, 2017, 199(2): 718-733.
[26] Guo C, Xie S, Chi Z, et al. Bile acids control inflammation and metabolic disorder through inhibition of NLRP3 inflammasome [J]. Immunity, 2016, 45(4): 802-816.
[27] Perino A, Pols TW, Nomura M, et al. TGR5 reduces macrophage migration through mTOR-induced C/EBPβ differential translation [J]. J Clin Invest, 2014, 124(12): 5424-5436.
[28] Podevin P, Calmus Y, Bonnefis MT, et al. Effect of cholestasis and bile acids on interferon-induced 2',5'-adenylate synthetase and NK cell activities [J]. Gastroenterology, 1995, 108(4): 1192-1198.
[29] Xun Z, Lin J, Yu Q, et al. Taurocholic acid inhibits the response to interferon-α therapy in patients with HBeAg-positive chronic hepatitis B by impairing CD8⁺ T and NK cell function [J]. Cell Mol Immunol, 2021, 18(2): 461-471.
[30] Rattay S, Graf D, Kislat A, et al. Anti-inflammatory consequences of bile acid accumulation in virus-infected bile duct ligated mice [J]. PLoS One, 2018, 13(6): e0199863. doi:10.1371/journal.pone.0199863.
[31] Song X, Sun X, Oh SF, et al. Microbial bile acid metabolites modulate gut RORγ⁺ regulatory T cell homeostasis [J]. Nature, 2020, 577(7790): 410-415.
[32] Hang S, Paik D, Yao L, et al.Bile acid metabolites control T(H)17 and T(reg)cell differentiation [J]. Nature, 2019, 576(7785): 143-148.
[33] Campbell C, McKenney PT, Konstantinovsky D, et al. Bacterial metabolism of bile acids promotes generation of peripheral regulatory T cells [J]. Nature, 2020, 581(7809): 475-479.
[34] Pols TWH, Puchner T, Korkmaz HI, et al. Lithocholic acid controls adaptive immune responses by inhibition of Th1 activation through the Vitamin D receptor [J]. PLoS One, 2017, 12(5): e0176715.
[35] Ichikawa R, Takayama T, Yoneno K, et al. Bile acids induce monocyte differentiation toward interleukin-12 hypo-producing dendritic cells via a TGR5-dependent pathway [J]. Immunology, 2012, 136(2): 153-162.
[36] Huh JR, Leung MW, Huang P, et al. Digoxin and its derivatives suppress TH17 cell differentiation by antagonizing RORγt activity [J]. Nature, 2011, 472(7344): 486-490.
[37] Ma C, Han M, Heinrich B, Fu Q, et al. Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells [J]. Science, 2018, 360(6391): 5931.
[38] Glaser F, John C, Engel B, et al. Liver infiltrating T cells regulate bile acid metabolism in experimental cholangitis [J]. J Hepatol, 2019, 71(4): 783-792.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed